Company: ARWR
Filing Date: 2025-10-10
Form Type: 10-K/A
Source: 0000879407-25-000013
Chunk: 29

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-10-10
Form: 10-K/A
Chunk 29
---
| Javier San Martin (1)                         
 Former Chief Medical Officer                  |     |               $582,400 |     |                $560,000 |     | 4%         |
| Tracie Oliver (2)                             
 Former Chief Commercial Officer               |     |               $488,880 |     |                $470,000 |     | 4%         |

(1) Dr. San Martin left the Company on February 1, 2024.
(2) Ms. Oliver served as the Company's Chief Commercial Officer until October 2024.

The actual base salaries paid to our NEOs in fiscal 2024 are set forth in the “Fiscal 2024 Summary Compensation Table” below.

Annual Cash Incentive Compensation

We provide our executive officers, including our NEOs, with the opportunity to earn performance-based annual incentive awards, payable in cash, which are designed to reward them for our overall corporate performance as well as their individual performance. Generally, our executive officers are evaluated each year for eligibility to receive an annual cash incentive compensation opportunity. Through a collaborative planning process involving our Board and management, corporate performance objectives are established at the beginning of each year and evaluated regularly by our Board for their continued relevance to our status.

Target Annual Cash Incentive Award Opportunities

For purposes of the fiscal 2024 performance-based incentive awards, each of our NEOs was assigned a target annual cash incentive award opportunity based upon a percentage of his or her base salary. The target annual cash incentive award opportunities for our executive officers, including our NEOs, were recommended by our CEO (except with respect to his own target annual cash incentive award opportunity) based on each executive officer’s accountability, scope of responsibilities, and potential impact on our performance, and approved by the Compensation Committee. The determination of target annual cash incentive award opportunities was also based on the factors described in “Governance of Executive Compensation Program - Compensation-Setting Process” above. Our NEOs’ target annual cash incentive award opportunities did not change from fiscal 2023.

The target cash annual incentive award opportunities for our NEOs were as follows:

| Named Executive Officer |     | Fiscal 2024 Target Annual Incentive AwardOpportunity (as  apercentage of basesalary) |     | Fiscal 2023 Target AnnualIncentive AwardOpportunity (as  apercentage of basesalary) |
| Dr. Anzalone (1)        |     | 100%                                                                                 |     | 100%                                                                                |
| Mr. Myszkowski